According to a new study published Monday in the journal Nature Medicine, weight loss drugs such as Ozempic and Monjaro may not only shrink waistlines but also reduce the risk of certain diseases, inc
luding Alzheimer's disease, heart disease and liver cancer. However, it has been found that these drugs may be linked to the risk of gastrointestinal disorders, arthritis, kidney damage and pancreatitis.
A study called Mapping the Efficacy and Risk of GLP-1 Receptor Agonists was conducted by scientists from the U. S. Department of Veterans Affairs in St. Louis and Ewha Womans University in Seoul, Korea. The study was conducted. The results showed that people taking GLP-1 agonists had a reduced risk of developing 42 diseases, including a 9 percent lower risk of heart attack and an 8 percent lower risk of dementia.
This study shows that treating obesity and metabolic syndrome has broad medical implications. It shows that this is very likely, said Dr. Ziyad Al-Ali, director of research and development at the VA St. Louis Healthcare System.
Released in December 2017 by pharmaceutical company Novo Nordisk, Ozempic is a prescription injectable drug for the treatment of type 2 diabetes in adults. It gained popularity after Novo Nordisk scientists discovered that the drug mimics natural hormones that suppress appetite and slow digestion, leading to weight loss in some users.
Ozempic is a medical miracle.
These drugs reduce brain inflammation and reduce weight. They also lead to weight loss. Both improve brain health and reduce the risk of diseases like Alzheimer's and dementia.
We know that obesity has a negative impact on many things. And now we have empirical evidence that treating obesity has health benefits that go beyond just weight loss, says Al #Ali . However, there are also risks. We hope that these results will provide food for discussion with patients and their physicians.
'
If you're a marathon runner, artificial intelligence will come to you on your run.
The U. S.
Read us at: Compass Investments
